If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

My doctoral programme investigates the immune cells that infiltrate tumours (TILs) which are the basis of immunotherapy, a relatively new set of very powerful cancer treatments. Immunotherapy could allow better cancer treatment by exploiting the ability of certain immune cells to identify and eliminate undesirable cells such as cancer cells. I aim to provide new insights into the genetic traits of the tumour-infiltrating cells to look for potential new druggable targets using Illumina and Oxford Nanopore sequencing technology. In addition, I am generating organoids from pancreatic cancer mouse models for co-culture with autologous peripheral blood lymphocytes. The goal is to isolate any reactive T cells from the pancreatic organoid-lymphocyte co-culture and to perform RNA sequencing – bulk and single cell – of the tumour-infiltrating lymphocytes.

Education/Academic qualification

Medicine, Doctor of Medicine, Università degli Studi di Trieste

1 Oct 201026 Jul 2016

Award Date: 26 Jul 2016

Medical Biotechology, Master of Biology, Università degli Studi di Trieste

Oct 2007Apr 2010

Award Date: 15 Apr 2010

Biotechnology, Bachelor of Science, Università degli Studi di Trieste

Oct 2003Jul 2007

Award Date: 18 Jul 2007

External positions

Medical Advisor, RNA Diagnostics

Mar 2018 → …


  • Tumour Microenvironment
  • Immunotherapy
  • Oncoimmunology
  • Nanoporesequencing
  • MinION
  • Immunology

Fingerprint Dive into the research topics where Alberto D'Angelo is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 5 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

An overview of the clinical use of cabozantinib in the treatment of advanced non-clear-cell renal cell carcinoma (NCCRCC)

D'Angelo, A., Bagby, S., Di Pierro, G., Chirra, M., Nobili, S., Mini, E., Villari, D. & Roviello, G., May 2020, In : Critical Reviews in Oncology/Hematology. 149, 102921.

Research output: Contribution to journalReview article


Association between neutropenia and response to ramucirumab and paclitaxel in patients with metastatic gastric cancer

Roviello, G., Conca, R., D'Angelo, A., Multari, A. G., Paganini, G., Chiriacò, G., Petrioli, R., Corona, S. P., Rosellini, P. & Aieta, M., Jul 2020, In : Anti-Cancer Drugs. 31, 6, p. 632-636

Research output: Contribution to journalArticle

Cabozantinib as a second-line treatment option in hepatocellular carcinoma

D’Angelo, A., Sobhani, N., Bagby, S., Casadei-Gardini, A. & Roviello, G., 12 May 2020, In : Expert Review of Clinical Pharmacology.

Research output: Contribution to journalReview article

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer

Roviello, G., D'Angelo, A., Petrioli, R., Roviello, F., Cianchi, F., Nobili, S., Mini, E. & Lavacchi, D., 26 May 2020, In : Translational Oncology. 13, 9, 100795.

Research output: Contribution to journalReview article

Open Access

Evaluation of targetable biomarkers for chimeric antigen receptor T-cell (CAR-T) in the treatment of pancreatic cancer: a systematic review and meta-analysis of preclinical studies

Sahlolbei, M., Dehghani, M., Kheiri Yeghane Azar, B., Vafaei, S., Roviello, G., D'Angelo, A., Madjd, Z. & Kiani, J., 16 Jun 2020, In : Exercise Immunology Review. p. 1-10 10 p.

Research output: Contribution to journalReview article